SynBioBeta Speaker
Per Falholt
21st.BIO
CSO, Co-founder
Per Falholt is a Danish chemical engineer with more than 40 years of experience in industrial biotechnology and innovation. He spent over three decades at Novo Nordisk and Novozymes, where he held senior leadership roles, including EVP of R&D, and was responsible for global research centers and the successful launch of around 200 new enzyme products across multiple industries.
Since 2016, he has co-founded several biotech companies, including Bactolife, Lactobio (sold to L’Oréal in 2023), ExelCyte, and 21st.BIO, where he serves as co-founder of a fast-growing Danish-American biotech firm. He is also an inventor on ~15 patents and contributed to pioneering enzyme technologies, large-scale protein production, and the application of CRISPR and other advanced biotech tools.
Falholt has served as Chairman of DTU’s Board (2012–2020) and currently holds board positions at Danfoss, Co-Ro, and several biotech ventures, as well as advisory roles at DTU and international life science companies.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Per
This Year
Session lineup still growing
Purchase Pass
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Purchase Pass
Featuring
Speaker Coming Soon
